Papillary Epinephrine Injection vs Rectal Indomethacin
NCT07173179
Post-ERCP Acute Pancreatitis
Düzce, Turkey (Türkiye)
View Trial DetailsNCT Number: NCT05310409
The aim of this study is to use a validated patient-reported outcome measure to evaluate how many patients have symptoms of pancreatitis after ERCP and how it correlates with their quality of life and productivity.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
University of California, San Francisco, San Francisco, California, United States
This project will measure the impact of a recently validated patient-reported outcome measure for acute pancreatitis, PAN-PROMISE, to detect post-ERCP pancreatitis symptoms and capture its morbidity. The study will compare the change of PAN-PROMISE before and after ERCP to the current standard diagnostic criteria for post-ERCP pancreatitis, the Cotton Consensus Criteria. The main limitations of the Cotton-Consensus Criteria are that it fails to capture outpatient or ambulatory morbidity, uses length of stay to define the severity of pancreatitis without accounting for local or systemic complications for pancreatitis, and it has limited sensitivity in patients with chronic symptoms such as patients with chronic pancreatitis or pancreatic adenocarcinoma. These limitations have impeded the evaluation of potential therapies to prevent post-ERCP pancreatitis. PAN-PROMISE will help capture and quantitate the morbidity related to post-ERCP pancreatitis and thus will enhance our ability to optimize outcomes following ERCP.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 7 days after ERCP
will define post-ERCP pancreatitis using the Cotton Consensus Criteria with a 3 physician adjudication committee.
Time frame: 30 days
will capture the work abseentism and loss of productivity using the Work-Productivity and Activity Impairment Questionnaire and will express in in 2021 US Dollars.
Time frame: 30 days
will capture the direct healthcare costs using the Medicare Reimbursement data and express it in 2021 US Dollars.
Time frame: 30 days
will capture changes in Quality of Life using the SF-12 instrument.
University of Pennsylvania
Other
A Prospective Cohort Study Evaluating PAN-PROMISE, a Patient-Reported Outcome Measure, To Detect and Risk-Stratify Post-ERCP Pancreatitis
Acronym: PAN-PROMISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07173179
Post-ERCP Acute Pancreatitis
Düzce, Turkey (Türkiye)
View Trial DetailsNCT05664074
Post-ERCP Acute Pancreatitis
Cincinnati, Ohio, United States
View Trial DetailsNCT07391787
Post-ERCP Acute Pancreatitis
Jinan, Shandong, China
View Trial DetailsNCT05336630
Post-ERCP Acute Pancreatitis
Lebanon, New Hampshire, United States
View Trial Details